👤 Fachen Zhou

🔍 Search 📋 Browse 🏷️ Tags ❤️ Favourites ➕ Add 🧬 Extraction
1335
Articles
847
Name variants
Also published as: Aiping Zhou, Aiwu Zhou, Alicia Y Zhou, An Zhou, Ang Zhou, Anna Y Zhou, Annan Zhou, Ao Zhou, Aojia Zhou, Aoshuang Zhou, Apei Zhou, Baiwan Zhou, Bao-Sen Zhou, Baohua Zhou, Baojuan Zhou, Baosen Zhou, Beixian Zhou, Beiyi Zhou, Bin Zhou, Bincheng Zhou, Bing Zhou, Bingbing Zhou, Binghai Zhou, Bingqian Zhou, Bingqing Zhou, Bingying Zhou, Binhua P Zhou, Binhua Zhou, Birong Zhou, Bo Zhou, Bo-Ya Zhou, Bo-Yang Zhou, Bubo Zhou, C Zhou, C-J Zhou, Can Zhou, Carl Zhou, Cefan Zhou, Chang Zhou, Chang-Yin Zhou, Changfan Zhou, Changhua Zhou, Changqi Zhou, Changrui Zhou, Changshuai Zhou, Changwen Zhou, Chao Zhou, Chen-Hui Zhou, Chen-Liang Zhou, Chenchen Zhou, Cheng Zhou, Chengji J Zhou, Chenhao Zhou, Chenkang Zhou, Chenqi Zhou, Chenxia Zhou, Chong Zhou, Chong-zhi Zhou, Chongwei Zhou, ChuHuan Zhou, Chuan-Min Zhou, Chuan-Wei Zhou, Chuan-Xiang Zhou, Chuan-chuan Zhou, Chuanen Zhou, Chuanman Zhou, Chuhao Zhou, Chun-Man Zhou, Chun-Ni Zhou, Chunlei Zhou, Chunlin Zhou, Chunni Zhou, Chunxian Zhou, Chunxiu Zhou, Chunyu Zhou, Chunzhuang Zhou, Chuyu Zhou, Cui Zhou, Cuiqi Zhou, Da Zhou, Daijun Zhou, Daizhan Zhou, Dan Zhou, Danmei Zhou, Danxia Zhou, Dao Zhou, David Zhou, Dawei Zhou, Daxin Zhou, Degang Zhou, Dejun Zhou, Dezheng Zhou, Dingan Zhou, Dingzi Zhou, Dong-Sheng Zhou, Dongdong Zhou, Donger Zhou, Dongfang Zhou, Donghai Zhou, Dongjie Zhou, Dongmei Zhou, Dongsheng Zhou, Duanfang Zhou, Duo-Qi Zhou, Duoqi Zhou, Enchen Zhou, Ershun Zhou, F Zhou, Fan Zhou, Fanfan Zhou, Fang Zhou, Fangfang Zhou, Fangli Zhou, Fangting Zhou, Fei Zhou, Feixue Zhou, Feiye Zhou, Feng Zhou, Feng-Quan Zhou, Fenghua Zhou, Fengrui Zhou, Fengyun Zhou, Fenling Zhou, Fu-Ling Zhou, Fude Zhou, Fuling Zhou, Fusheng Zhou, Fuxiang Zhou, Fuyou Zhou, G Zhou, Gang Zhou, Grace Guoying Zhou, Guangji Zhou, Guangjun Zhou, Guangming Zhou, Guangqian Zhou, Guangzhou Zhou, Gui-Feng Zhou, Guifeng Zhou, Guiju Zhou, Guili Zhou, Guiting Zhou, Guo Zhou, Guo-Kun Zhou, Guohong Zhou, Guohua Zhou, Guoli Zhou, Guoyu Zhou, Guyue Zhou, H Zhou, Haibo Zhou, Haihong Zhou, Haihua Zhou, Haijing Zhou, Haimei Zhou, Hairui Zhou, Haixu Zhou, Haiyan Zhou, Haiyuan Zhou, Haiyue Zhou, Han Zhou, Hang Zhou, Hang-Yu Zhou, Hangfan Zhou, Hanshen Zhou, Hanxiao Zhou, Hao Zhou, Hao-Min Zhou, Haobo Zhou, Haonan Zhou, Haoxiong Zhou, Haoyuan Zhou, He Zhou, Helen Zhou, HengCui Zhou, Heying Zhou, Hong Zhou, Hong-Yu Zhou, Honghong Zhou, Hongji Zhou, Honglei Zhou, Hongli Zhou, Hongmei Zhou, Hongmin Zhou, Hongshan Zhou, Hongwei Zhou, Hongwen Zhou, Hongyan Zhou, Hou-De Zhou, Hu Zhou, Hua Ying Zhou, Hua Zhou, Hua-Bang Zhou, Huadong Zhou, Huaijun Zhou, Huamao Zhou, Huan Zhou, Huangao Zhou, Huanjin Zhou, Huanyu Zhou, Huaqiang Zhou, Hui Zhou, Hui-Fen Zhou, Huifang Zhou, Huifen Zhou, Huihui Zhou, Huimin Zhou, Huinian Zhou, Huiqiang Zhou, Huiwen Zhou, J Zhou, Jeff Xiwu Zhou, Ji Zhou, Ji-Chao Zhou, Ji-Ying Zhou, Jia Zhou, Jia-Guo Zhou, Jia-le Zhou, Jiahe Zhou, Jiahua Zhou, Jiajie Zhou, Jiale Zhou, Jiamei Zhou, Jian Zhou, Jian-Peng Zhou, JianJiang Zhou, Jianan Zhou, Jianfen Zhou, Jianfeng Zhou, Jiang-Ning Zhou, Jiangfei Zhou, Jianghao Zhou, Jianghong Zhou, Jianghui Zhou, Jianglin Zhou, Jiangqiao Zhou, Jianguo Zhou, Jianhua Zhou, Jianling Zhou, Jianmin Zhou, Jianqing Zhou, Jianshe Zhou, Jianwei Zhou, Jianying Zhou, Jianzhong Zhou, Jiaqi Zhou, Jiaru Zhou, Jiawang Zhou, Jiawei Zhou, Jiawen Zhou, Jiaxi Zhou, Jiaxiang Zhou, Jiaxin Zhou, Jiayan Zhou, Jiayi Zhou, Jiayin Zhou, Jie Zhou, Jiechao Zhou, Jiefu Zhou, Jieru Zhou, Jieyan Zhou, Jieyu Zhou, Jin Zhou, Jin-Ting Zhou, Jin-Yong Zhou, JinQiu Zhou, Jing Zhou, Jing-Wei Zhou, Jing-Xuan Zhou, Jingbo Zhou, Jingjie Zhou, Jingjing Zhou, Jingjun Zhou, Jingpei Zhou, Jingqi Zhou, Jingwen Zhou, Jingyi Zhou, Jingyu Zhou, Jingyuan Zhou, Jinting Zhou, Jinyi Zhou, Jiuyao Zhou, Jiyong Zhou, John Zhou, Ju Zhou, Juan Zhou, Juanjuan Zhou, Jue-Yu Zhou, Julian Q Zhou, Jun Zhou, Jun-Min Zhou, Jun-Ying Zhou, Jun-Yu Zhou, Jundong Zhou, Junfeng Zhou, Jungu Zhou, Junguo Zhou, Junhe Zhou, Junjie Zhou, Junjun Zhou, Junting Zhou, Junya Zhou, Junyu Zhou, Justin Zhou, Juying Zhou, Kaicheng Zhou, Kaixia Zhou, Kaixin Zhou, Kaiyu Zhou, Kan Zhou, Ke Zhou, Kecheng Zhou, Kefu Zhou, Kejin Zhou, Kexun Zhou, Lamei Zhou, Lan Zhou, Lang Zhou, Lanlan Zhou, Lanping Zhou, Lanqi Zhou, Laura Y Zhou, Le Zhou, Lei Zhou, Lei-Lei Zhou, Li Zhou, Li-Jun Zhou, Liang Zhou, Liangdong Zhou, Liangfu Zhou, Liangrui Zhou, Liangxue Zhou, Liangyu Zhou, Libin Zhou, Libing Zhou, Libo Zhou, Liche Zhou, Lihong Zhou, Lihuan Zhou, Lijun Zhou, Lili Zhou, Limin Zhou, Lin Zhou, Lina Zhou, Linda Zhou, Ling Zhou, Ling-Yun Zhou, Linglin Zhou, Lingshan Zhou, Lingyi Zhou, Lingyun Zhou, Linjun Zhou, Linnan Zhou, Linran Zhou, Lipeng Zhou, Liqun Zhou, Lisha Zhou, Lisheng Zhou, Liting Zhou, Liufang Zhou, Liuqing Zhou, Liuxin Zhou, Lixin Zhou, Liye Zhou, Long Zhou, Lu Zhou, Lufang Zhou, Luling Zhou, Luming Zhou, Lunni Zhou, Luo-Qi Zhou, Luting Zhou, M M Zhou, Maoge Zhou, Maotian Zhou, Mei Zhou, Meijing Zhou, Meilan Zhou, Meiqi Zhou, Meirong Zhou, Meiyi Zhou, Meng-Tao Zhou, Meng-Yao Zhou, Menghua Zhou, Mengkai Zhou, Menglong Zhou, Mengna Zhou, Mengqi Zhou, Mengqian Zhou, Mengze Zhou, Mi Zhou, Miao Zhou, Min Zhou, Ming Zhou, Ming-Ju Zhou, Ming-Ming Zhou, Ming-Sheng Zhou, Mingfeng Zhou, Minglei Zhou, Minglian Zhou, Mingmei Zhou, Mingming Zhou, Mingping Zhou, Mingqi Zhou, Minling Zhou, Minyi Zhou, Molin Zhou, Na Zhou, Nan Zhou, Neng Zhou, Ni Zhou, Nian Zhou, Nianwei Zhou, Ning Zhou, Ningying Zhou, Niuniu Zhou, P Zhou, Pei Zhou, Peng Zhou, Penghui Zhou, Pijun Zhou, Ping Zhou, Ping-Kun Zhou, Pingkun Zhou, Pingxi Zhou, Pingxin Zhou, Puhui Zhou, Q Zhou, Qi Zhou, Qian Zhou, Qiang Zhou, Qianxin Zhou, Qiao Zhou, Qiaoxia Zhou, Qidong Zhou, Qin Zhou, Qin-Yi Zhou, Qing Zhou, Qing-Bing Zhou, Qing-Qing Zhou, Qingbing Zhou, Qingbo Zhou, Qingchun Zhou, Qinghua Zhou, Qingniao Zhou, Qingnv Zhou, Qingping Zhou, Qingtong Zhou, Qingxin Zhou, Qingyu Zhou, Qiong Zhou, Qiu-Min Zhou, Qiu-Zhi Zhou, Qiyang Zhou, Qiyin Zhou, Quan Zhou, Qun Zhou, R B Zhou, Ranran Zhou, Raorao Zhou, Ren Zhou, Rong Zhou, Rong-Yan Zhou, Rongbin Zhou, Rongjia Zhou, Rongxian Zhou, Rongxuan Zhou, Rongyan Zhou, Rouxi Zhou, Ru Zhou, Ruchen Zhou, Rui Zhou, Ruihai Zhou, Ruijun Zhou, Ruimei Zhou, Ruisi Zhou, Runjin Zhou, Ruyi Zhou, S A Zhou, S R Zhou, S Zhou, S-G Zhou, Sa Zhou, Sanshun Zhou, Sha Zhou, Shanshan Zhou, Shao-Lai Zhou, Shaobo Zhou, Shaoli Zhou, Shaolong Zhou, Sheng-Nan Zhou, Shenghua Zhou, Shenghui Zhou, Shengwen Zhou, Shengyang Zhou, Shengyi Zhou, Shenping Zhou, Shiao Zhou, Shibo Zhou, Shiyi Zhou, Shu Zhou, Shuaishuai Zhou, Shuaiyang Zhou, Shuang Zhou, Shuling Zhou, Shumin Zhou, Shun Zhou, Shuo Zhou, Si Zhou, Si-Qi Zhou, Siquan Zhou, Sirui Zhou, Song Zhou, Songhui Zhou, Sufang Zhou, Sumei Zhou, Suqing Zhou, Suzhen Zhou, T Zhou, Tai-Cheng Zhou, Taimei Zhou, Tao Zhou, Tengxiao Zhou, Ti Zhou, Tian-Li Zhou, Tianhua Zhou, Tianqiong Zhou, Tianrong Zhou, Tianxing Zhou, Tianyan Zhou, Tianyu Zhou, Tiger Zhou, Ting Zhou, Tingting Zhou, Tong Zhou, Vincent Zhou, W Zhou, Wan-hao Zhou, Wang Zhou, Wei Zhou, Weihua Zhou, Weihui Zhou, Weijiao Zhou, Weijie Zhou, Weiming Zhou, Weinan Zhou, Weiqiang Zhou, Weishang Zhou, Weiwei Zhou, Weiying Zhou, Wen Zhou, Wen-Chao Zhou, Wen-Hao Zhou, Wen-Jie Zhou, Wen-Quan Zhou, Wenbin Zhou, Wenbo Zhou, Wenchao Zhou, Wenfang Zhou, Wenhao Zhou, Wenjie Zhou, Wenjing Zhou, Wenke Zhou, Wenqing Zhou, Wenrong Zhou, Wenwen Zhou, Wenxing Zhou, Wenyu Zhou, Wenzong Zhou, Wesley Zhou, Wu Zhou, Wuduo Zhou, Wuyuan Zhou, X F Zhou, X Q Zhou, X-T Zhou, Xi Zhou, Xia Zhou, Xia-Bo Zhou, Xiang Zhou, Xiangda Zhou, Xiangdong Zhou, Xianghai Zhou, Xiangrong Zhou, Xianguo Zhou, Xiangyu Zhou, Xiangyuan Zhou, Xianhu Zhou, Xianhua Zhou, Xianhui Zhou, Xianjing Zhou, Xianliang Zhou, Xianxiao Zhou, Xiao Zhou, Xiao-Hai Zhou, Xiao-Ting Zhou, Xiao-Yu Zhou, Xiaobo Zhou, Xiaochuan Zhou, Xiaochun Zhou, Xiaofeng Zhou, Xiaohai Zhou, Xiaohan Zhou, Xiaohui Zhou, Xiaojing Zhou, Xiaolei Zhou, Xiaoli Zhou, Xiaolin Zhou, Xiaoling Zhou, Xiaomao Zhou, Xiaoming Zhou, Xiaonan Zhou, Xiaopu Zhou, Xiaoqian Zhou, Xiaorong Zhou, Xiaorui Zhou, Xiaoshu Zhou, Xiaosu Zhou, Xiaotong Zhou, Xiaowen Zhou, Xiaoxi Zhou, Xiaoxia Zhou, Xiaoxue Zhou, Xiaoyan Zhou, Xiaoye Zhou, Xiaoying Zhou, Xiaozhong Zhou, Xidan Zhou, Xin Tong Zhou, Xin Zhou, Xin-Rong Zhou, Xin-Yu Zhou, Xin-Yue Zhou, Xingtao Zhou, Xinhong Zhou, Xinhua Zhou, Xinming Zhou, Xinyan Zhou, Xinyao Zhou, Xinyi Zhou, Xinyue Zhou, Xinzhi Zhou, Xiqiu Zhou, Xiu-Ping Zhou, Xiuhong Zhou, Xiuling Zhou, Xiuping Zhou, Xiuteng Zhou, Xiyi Zhou, Xu Yu Zhou, Xu Zhou, Xu-Hua Zhou, Xuan Zhou, Xuanchen Zhou, Xuchang Zhou, Xue Dong Zhou, Xue Zhou, Xue-Yan Zhou, Xuedong Zhou, Xuefeng Zhou, Xuejie Zhou, Xueli Zhou, Xueliang Zhou, Xueqin Zhou, Xueqing Zhou, Xueshi Zhou, Xujie Zhou, Xun Zhou, Xuyu Zhou, Y J Zhou, Y Zhou, Y-L Zhou, Yachuan Zhou, Yadi Zhou, Yahui Zhou, Yajun Zhou, Yan Zhou, Yan-Yan Zhou, Yanbing Zhou, Yandong Zhou, Yanfen Zhou, Yang Zhou, Yangbo Zhou, Yangying Zhou, Yanhao Zhou, Yanheng Zhou, Yanhua Zhou, Yanjiao Zhou, Yanjie Zhou, Yanli Zhou, Yanling Zhou, Yanmeng Zhou, Yanqiu Zhou, Yanrong Zhou, Yanyi Zhou, Yao Zhou, Yaping Zhou, Yaqi Zhou, Yating Zhou, Yeyun Zhou, Yi Zhou, Yi-Hui Zhou, Yi-Jiang Zhou, Yichao Zhou, Yidan Zhou, Yifa Zhou, Yifeng Zhou, Yinan Zhou, Ying Zhou, Ying-Hui Zhou, Yinghui Zhou, Yingjie Zhou, Yingmin Zhou, Yingshi Zhou, Yiqing Zhou, Yitian Zhou, Yong Zhou, Yong-Gang Zhou, Yong-Hui Zhou, Yong-an Zhou, Yongbing Zhou, Yongcan Zhou, Yonghua Zhou, Yongjian Zhou, Yongqiang Zhou, Yongtao Zhou, Yongxin Zhou, Yongzhi Zhou, You Lang Zhou, You Zhou, You-Li Zhou, Youping Zhou, Yu Zhou, Yu-Bao Zhou, Yu-Ning Zhou, Yu-Qi Zhou, Yuan Zhou, Yuanyuan Zhou, Yubin Zhou, Yudong Zhou, Yue Zhou, Yueping Zhou, Yuetao Zhou, Yufei Zhou, Yuhan Zhou, Yuhuan Zhou, Yujia Zhou, Yujie Zhou, Yun Zhou, Yun-Fei Zhou, Yun-Tao Zhou, Yunfang Zhou, Yunfeng Zhou, Yunhui Zhou, Yunqian Zhou, Yunxia Zhou, Yunxiang Zhou, Yunyun Zhou, Yunzhen Zhou, Yuqi Zhou, Yuqiao Zhou, Yuqing Zhou, Yuqiu Zhou, Yushan Zhou, Yuting Zhou, Yutong Zhou, Yuxin Zhou, Yuzhi Zhou, Zechen Zhou, Zefeng Zhou, Zenghui Zhou, Zengyuan Zhou, Zengzi Zhou, Zewei Zhou, Zhan Zhou, Zhaokai Zhou, Zhechong Zhou, Zhen Zhou, Zheng Zhou, Zheng-Jun Zhou, Zheng-Yang Zhou, Zhengyang Zhou, Zhengzhong Zhou, Zhenhua Zhou, Zhenlei Zhou, Zhenying Zhou, Zhenyu Zhou, Zheyi Zhou, Zhi Dong Zhou, Zhi Zhou, Zhi-Dong Zhou, Zhi-Gang Zhou, Zhi-Hang Zhou, Zhi-Jiao Zhou, Zhi-Xiang Zhou, Zhi-Yong Zhou, Zhibo Zhou, Zhicheng Zhou, Zhifeng Zhou, Zhiguang Zhou, Zhihang Zhou, Zhihao Zhou, Zhiheng Zhou, Zhihui Zhou, Zhijiao Zhou, Zhijun Zhou, Zhimin Zhou, Zhipeng Zhou, Zhiqin Zhou, Zhiqun Zhou, Zhiwei Zhou, Zhixiang Zhou, Zhiyi Zhou, Zhiyong Zhou, Zhiyu Zhou, Zhongbo Zhou, Zhongjiang Zhou, Zhongkai Zhou, Zhongqiu Zhou, Zhongtao Zhou, Zhongxing Zhou, Zhongyin Zhou, Zhou Zhou, Zhu Zhou, Zhuoming Zhou, Zi-Yang Zhou, Zi-Yi Zhou, Zihan Zhou, Zihao Zhou, Zihua Zhou, Zijun Zhou, Zili Zhou, Ziliang Zhou, Zilin Zhou, Zilong Zhou, Zipeng Zhou, Ziqing Zhou, Ziwei Zhou, Ziyan Zhou, Ziyue Zhou, Ziyun Zhou, Zongkai Zhou, Zunchun Zhou, Zuomin Zhou, Zuoqiong Zhou, Zuping Zhou
articles
Minghua Li, Yanhong Wang, Xiaoyang Lin +8 more · 2024 · Exploration of targeted anti-tumor therapy · added 2026-04-24
The main objective of this study was to investigate the antitumor effect of a mouse anti-human glypican-1 (GPC1) monoclonal antibody (mAb) on non-small cell lung carcinoma (NSCLC) and associated molec Show more
The main objective of this study was to investigate the antitumor effect of a mouse anti-human glypican-1 (GPC1) monoclonal antibody (mAb) on non-small cell lung carcinoma (NSCLC) and associated molecular mechanisms. The anti-proliferative and anti-migratory activities of anti-GPC1 mAb were examined in A549 and H460 NSCLC cells and LL97A lung fibroblasts. The inhibitory effect of anti-GPC1 mAb on tumor growth was evaluated in an orthotopic lung tumor model. The in vitro study showed that anti-GPC1 mAb profoundly inhibited the anchorage-independent growth of A549 and H460 NSCLC cells and exhibited relatively high cytotoxic activities towards LL97A lung fibroblasts, A549/LL97A and H460/LL97A coculture spheroids. Moreover, anti-GPC1 mAb significantly decreased the expression of phospho-Src (p-Src; Tyr416), p-Akt (Ser473) and β-catenin in the co-cultured LL97A lung fibroblasts, and the expression of phospho-mitogen-activated protein kinase kinase (p-MEK; Ser217/221) and phospho-90 kDa ribosomal s6 kinase (p-p90RSK; Ser380) in co-cultured A549 cells. When anti-GPC1 mAb was administered to tumor-bearing mice, the inhibitory effect of anti-GPC1 mAb on the orthotopic lung tumor growth was not statistically significant. Nonetheless, results of Western blot analysis showed significant decrease in the phosphorylation of fibroblast growth factor receptor 1 (FGFR1) at Tyr766, Src at Tyr416, extracellular signal-regulated kinase (ERK) at Thr202/Tyr204, 90 kDa ribosomal S6 kinase (RSK) at Ser380, glycogen synthase kinases 3α (GSK3α) at Ser21 and GSK3β at Ser9 in tumor tissues. These data implicate that anti-GPC1 mAb treatment impairs the interaction between tumor cells and tumor associated fibroblasts by attenuating the paracrine FGFR signal transduction. The relatively potent cytotoxicity of anti-GPC1 mAb in lung fibroblasts and its potential inhibitory effect on the paracrine FGFR signal transduction warrant further studies on the combined use of this mAb with targeted therapeutics to improve therapeutic outcomes in lung cancer. Show less
📄 PDF DOI: 10.37349/etat.2024.00238
FGFR1
Wuqing Deng, Xiaojuan Chen, Hong Liang +7 more · 2024 · European journal of medicinal chemistry · Elsevier · added 2026-04-24
The aberrant activation of FGFRs plays a critical role in various cancers, leading to the development of several FGFR inhibitors in clinic. However, the emergence of drug resistance, primarily due to Show more
The aberrant activation of FGFRs plays a critical role in various cancers, leading to the development of several FGFR inhibitors in clinic. However, the emergence of drug resistance, primarily due to gatekeeper mutations in FGFRs, has limited their clinical efficacy. To address the unmet medical need, a series of 5-amino-1H-pyrazole-4-carboxamide derivatives were designed and synthesized as novel pan-FGFR covalent inhibitors targeting both wild-type and the gatekeeper mutants. The representative compound 10h demonstrated nanomolar activities against FGFR1, FGFR2, FGFR3 and FGFR2 V564F gatekeeper mutant in biochemical assays (IC Show less
no PDF DOI: 10.1016/j.ejmech.2024.116558
FGFR1
Baotong Zhang, Mingcheng Liu, Fengyi Mai +13 more · 2024 · The Journal of clinical investigation · added 2026-04-24
Inactivation of phosphatase and tensin homolog (PTEN) is prevalent in human prostate cancer and causes high-grade adenocarcinoma with a long latency. Cancer-associated fibroblasts (CAFs) play a pivota Show more
Inactivation of phosphatase and tensin homolog (PTEN) is prevalent in human prostate cancer and causes high-grade adenocarcinoma with a long latency. Cancer-associated fibroblasts (CAFs) play a pivotal role in tumor progression, but it remains elusive whether and how PTEN-deficient prostate cancers reprogram CAFs to overcome the barriers for tumor progression. Here, we report that PTEN deficiency induced Krüppel-like factor 5 (KLF5) acetylation and that interruption of KLF5 acetylation orchestrated intricate interactions between cancer cells and CAFs that enhance FGF receptor 1 (FGFR1) signaling and promote tumor growth. Deacetylated KLF5 promoted tumor cells to secrete TNF-α, which stimulated inflammatory CAFs to release FGF9. CX3CR1 inhibition blocked FGFR1 activation triggered by FGF9 and sensitized PTEN-deficient prostate cancer to the AKT inhibitor capivasertib. This study reveals the role of KLF5 acetylation in reprogramming CAFs and provides a rationale for combined therapies using inhibitors of AKT and CX3CR1. Show less
📄 PDF DOI: 10.1172/JCI175949
FGFR1
Jun Zhou, Haoran Yu, Hong Zeng +3 more · 2024 · Digestive and liver disease : official journal of the Italian Society of Gastroenterology and the Italian Association for the Study of the Liver · Elsevier · added 2026-04-24
Intrahepatic Cholangiocarcinoma (iCCA) with FGFR alterations is relatively rare, and its identification is important in the era of targeted therapy. We collected a large series of FGFR-altered cases i Show more
Intrahepatic Cholangiocarcinoma (iCCA) with FGFR alterations is relatively rare, and its identification is important in the era of targeted therapy. We collected a large series of FGFR-altered cases in the Chinese population and characterized their clinicopathological and genetic features. Among the 18 FGFR-altered cases out of 260 iCCAs, 10 were males and 8 were females, ranging in age from 35 to 74 years (mean, 57.3 years; median, 58 years). Pathologically, they include 9 cases of large duct (LD, 50 %) and small duct (SD, 50 %) types each. All of them (100 %, 18/18) showed microsatellite stable (MSS) and low tumor mutation burden (TMB). Genetically, FGFR alterations involved FGFR1 (20 %), FGFR2 (70 %), and FGFR3 (10 %), with FGFR2 rearrangement accounting for the most (11/18). The most frequently altered genes/biological processes were development/proliferation-related pathways (44 %), chromatin organization (20 %), and tumor suppressors (32 %). Our study further revealed the clinicopathological and genetic features of FGFR-altered iCCA and demonstrated that its occurrence may show regional or ethnic variability and is less common in the Chinese population. A significant number of LD-type iCCA cases also have FGFR alterations rather than the SD type. Show less
no PDF DOI: 10.1016/j.dld.2024.04.025
FGFR1
Huiqiong Li, Ran Ke, Yang Zhou +8 more · 2024 · European journal of medicinal chemistry · Elsevier · added 2026-04-24
Fibroblast growth factor receptor 2 (FGFR2) represents an appealing therapeutic target for multiple cancers, yet no selective FGFR2 inhibitors have been approved for clinical use to date. Here, we rep Show more
Fibroblast growth factor receptor 2 (FGFR2) represents an appealing therapeutic target for multiple cancers, yet no selective FGFR2 inhibitors have been approved for clinical use to date. Here, we report the discovery of a series of new selective, irreversible FGFR2 inhibitors. The representative compound LHQ490 potently inhibited FGFR2 kinase activity with an IC Show less
no PDF DOI: 10.1016/j.ejmech.2024.116473
FGFR1
Xiao-Ting Zhou, An-Qi Zhu, Xiao-Min Li +7 more · 2024 · Frontiers in endocrinology · Frontiers · added 2026-04-24
Obesity, a multifactorial disease with many complications, has become a global epidemic. Weight management, including dietary supplementation, has been confirmed to provide relevant health benefits. H Show more
Obesity, a multifactorial disease with many complications, has become a global epidemic. Weight management, including dietary supplementation, has been confirmed to provide relevant health benefits. However, experimental evidence and mechanistic elucidation of dietary supplements in this regard are limited. Here, the weight loss efficacy of MHP, a commercial solid beverage consisting of mulberry leaf aqueous extract and Show less
📄 PDF DOI: 10.3389/fendo.2024.1344262
FGFR1
Shiyi Fang, Lanzhu Peng, Mengmin Zhang +12 more · 2024 · Environmental toxicology · Wiley · added 2026-04-24
Tumor cell metastasis is the key cause of death in patients with nasopharyngeal carcinoma (NPC). MiR-2110 was cloned and identified in Epstein-Barr virus (EBV)-positive NPC, but its role is unclear in Show more
Tumor cell metastasis is the key cause of death in patients with nasopharyngeal carcinoma (NPC). MiR-2110 was cloned and identified in Epstein-Barr virus (EBV)-positive NPC, but its role is unclear in NPC. In this study, we investigated the effect of miR-2110 on NPC metastasis and its related molecular basis. In addition, we also explored whether miR-2110 can be regulated by cinobufotalin (CB) and participate in the inhibition of CB on NPC metastasis. Bioinformatics, RT-PCR, and in situ hybridization were used to observe the expression of miR-2110 in NPC tissues and cells. Scratch, Boyden, and tail vein metastasis model of nude mouse were used to detect the effect of miR-2110 on NPC metastasis. Western blot, Co-IP, luciferase activity, colocalization of micro confocal and ubiquitination assays were used to identify the molecular mechanism of miR-2110 affecting NPC metastasis. Finally, miR-2110 induced by CB participates in CB-stimulated inhibition of NPC metastasis was explored. The data showed that increased miR-2110 significantly suppresses NPC cell migration, invasion, and metastasis. Suppressing miR-2110 markedly restored NPC cell migration and invasion. Mechanistically, miR-2110 directly targeted FGFR1 and reduced its protein expression. Decreased FGFR1 attenuated its recruitment of NEDD4, which downregulated NEDD4-induced phosphatase and tensin homolog (PTEN) ubiquitination and degradation and further increased PTEN protein stability, thereby inactivating PI3K/AKT-stimulated epithelial-mesenchymal transition signaling and ultimately suppressing NPC metastasis. Interestingly, CB, a potential new inhibitory drug for NPC metastasis, significantly induced miR-2110 expression by suppressing PI3K/AKT/c-Jun-mediated transcription inhibition. Suppression of miR-2110 significantly restored cell migration and invasion in CB-treated NPC cells. Finally, a clinical sample assay indicated that reduced miR-2110 was negatively correlated with NPC lymph node metastasis and positively related to NPC patient survival prognosis. In summary, miR-2110 is a metastatic suppressor involving in CB-induced suppression of NPC metastasis. Show less
no PDF DOI: 10.1002/tox.24197
FGFR1
Q Lu, N Wang, K Jiang +6 more · 2024 · ESMO open · Elsevier · added 2026-04-24
Breast cancer brain metastasis (BCBM) is a crucial issue in the treatment of breast cancer and is associated with poor prognosis. Therefore, novel therapeutic targets are urgently needed in clinical p Show more
Breast cancer brain metastasis (BCBM) is a crucial issue in the treatment of breast cancer and is associated with poor prognosis. Therefore, novel therapeutic targets are urgently needed in clinical practice. In this study, we aimed to identify potential actionable targets in brain metastases (BMs) utilising the FoundationOne® CDx (F1CDx). Formalin-fixed paraffin-embedded archived specimens including 16 primary breast tumours (PTs), 49 BCBMs and 7 extracranial metastases (ECMs) from 54 patients who underwent surgery for BCBM were tested using F1CDx. Tumour-infiltrated lymphocytes (TILs) of BMs were also tested using haematoxylin-eosin staining. The median tumour mutational burden (TMB) and TILs in BMs were 5.0 (range 0-29) mut/Mb and 1.0% (range 0%-5.0%), respectively. High TMB (≥10 mut/Mb) was detected in four cases (8%). Genomic alterations (GAs) were detected in all samples. The top-ranked somatic mutations in BMs were TP53 (82%), PIK3CA (35%), MLL2 (22%), BRCA2 (14%) and ATM (14%) and the most prevalent copy number alterations were ERBB2 (64%), RAD21 (36%), CCND1 (32%), FGF19 (30%) and FGF3 (30%). The most prevalent GAs were relatively consistent between paired PTs and BMs. Actionable GAs were detected in 94% of all BMs. Consistent rate in actionable GAs was 38% (6/16) between paired PTs/ECMs and BMs. Compared to matched PTs/ECMs, additional actionable GAs (BRAF, FGFR1, PTEN, KIT and CCND1) were discovered in 31% (5/16) of the BMs. TMB and TILs were relatively low in BCBMs. Comparable consistency in actionable GAs was identified between BCBMs and matched PTs/ECMs. It was, therefore, logical to carry out genomic testing for BCBMs to identify potential new therapeutic targets when BCBM specimens were available, as ∼31% of samples carried additional actionable GAs. Show less
📄 PDF DOI: 10.1016/j.esmoop.2024.102389
FGFR1
Ge Tian, Jing Li, Wenjie Wang +1 more · 2024 · Drug development research · Wiley · added 2026-04-24
Fibroblast growth factor-12 (FGF12) has been reported to play important role in regulating heart diseases. We aimed to explore the role of FGF12 in doxorubicin (DOX)-induced myocardial injury. DOX-ind Show more
Fibroblast growth factor-12 (FGF12) has been reported to play important role in regulating heart diseases. We aimed to explore the role of FGF12 in doxorubicin (DOX)-induced myocardial injury. DOX-induced mice and DOX-induced HL-1 cells were used as the myocardial injury in vivo and in vitro. Then, FGF12, Anp, Bnp, and Myh7 expression was detected. The pathological injury in myocardium tissue was observed by H&E staining. The levels of markers related to myocardial damage and oxidative stress were assessed. Then, immunohistochemistry and immunofluorescence staining were used to detect FGF12 and 4-HNE expression. Ferroptosis were detected by Prussian blue staining and western blot. The FGFR1/AMPK/NRF2 signaling was measured by western blot. FGF12 expression was downregulated in DOX-induced mice myocardium tissues. FGF12 overexpression alleviated DOX-induced myocardial tissue pathological injury and reduced Anp, Bnp, and Myh7 expression. Additionally, the levels of CK-MB, LDH and cTnT in serum were decreased after FGF12 upregulation in DOX-induced mice. Moreover, FGF12 overexpression reduced the levels of ROS, MDA, and 4-HNE but increased SOD and GSH-Px activities. Meanwhile, FGF12 led to less deposition of iron ion, decreased ACSL4, PTGS2 and increased GPX4, FTH1 expression. Additionally, FGF12 activated the expressions of FGFR1, p-AMPK, and NRF2. Moreover, FGFR1 silencing reversed the protective effects of FGF12 overexpression on cell viability, oxidative stress, ferroptosis, and FGFR1/AMPK/NRF2 pathway. To sum up, FGF12 inhibited mitochondria-dependent ferroptosis in cardiomyocytes induced by DOX through activation of FGFR1/AMPK/NRF2 signaling. These findings clarify a new mechanism of DOX-induced cardiac injury and provide a promising target to limit the disease development. Show less
no PDF DOI: 10.1002/ddr.22149
FGFR1
Li Yin, Enming Zhang, Tianqi Mao +10 more · 2024 · Acta pharmaceutica Sinica. B · Elsevier · added 2026-04-24
Purinergic signaling plays a causal role in the modulation of immune inflammatory response in the course of psoriasis, but its regulatory mechanism remains unclear. As a member of purinoceptors, P2Y
📄 PDF DOI: 10.1016/j.apsb.2024.06.008
IL27
Feng Xiong, Kai Shen, Di Long +8 more · 2024 · Immunity & ageing : I & A · BioMed Central · added 2026-04-24
Systemic lupus erythematosus (SLE) is an autoimmune disorder that commonly affects the skin, kidneys, joints, and various other systemic tissues, with its development intricately linked to the process Show more
Systemic lupus erythematosus (SLE) is an autoimmune disorder that commonly affects the skin, kidneys, joints, and various other systemic tissues, with its development intricately linked to the process of immunosenescence. Quercetin (QC), a phytochemical that occurs naturally, demonstrates many different biological capabilities, such as antibacterial, antioxidant, and anti-inflammatory activities. Our investigation found that QC effectively reduced kidney damage and relieved mesenteric lymph nodes (mLNs) swelling in MRL/lpr lupus mice. Moreover, QC has been found to decrease the number of senescent follicular helper T (Tfh) cells, a pivotal kind of T cells that contribute to the progression of SLE. In vitro, QC exhibited the capacity to modulate mRNA expression levels, with the downregulation of IL-6, IL21-AS1, IL-27, BCL6, and BCL2L12, and the upregulation of FOXP1 and BIM. This modulation resulted in the suppression of Tfh cells differentiation and the enhancement of apoptosis in senescent CD4 Show less
📄 PDF DOI: 10.1186/s12979-024-00474-9
IL27
Nándor Gábor Than, Roberto Romero, Wendy Fitzgerald +13 more · 2024 · American journal of reproductive immunology (New York, N.Y. : 1989) · Blackwell Publishing · added 2026-04-24
Preeclampsia is a heterogeneous syndrome of diverse etiologies and molecular pathways leading to distinct clinical subtypes. Herein, we aimed to characterize the extracellular vesicle (EV)-associated Show more
Preeclampsia is a heterogeneous syndrome of diverse etiologies and molecular pathways leading to distinct clinical subtypes. Herein, we aimed to characterize the extracellular vesicle (EV)-associated and soluble fractions of the maternal plasma proteome in patients with preeclampsia and to assess their value for disease prediction. This case-control study included 24 women with term preeclampsia, 23 women with preterm preeclampsia, and 94 healthy pregnant controls. Blood samples were collected from cases on average 7 weeks before the diagnosis of preeclampsia and were matched to control samples. Soluble and EV fractions were separated from maternal plasma; EVs were confirmed by cryo-EM, NanoSight, and flow cytometry; and 82 proteins were analyzed with bead-based, multiplexed immunoassays. Quantile regression analysis and random forest models were implemented to evaluate protein concentration differences and their predictive accuracy. Preeclampsia subgroups defined by molecular profiles were identified by hierarchical cluster analysis. Significance was set at p < 0.05 or false discovery rate-adjusted q < 0.1. In preterm preeclampsia, PlGF, PTX3, and VEGFR-1 displayed differential abundance in both soluble and EV fractions, whereas angiogenin, CD40L, endoglin, galectin-1, IL-27, CCL19, and TIMP1 were changed only in the soluble fraction (q < 0.1). The direction of changes in the EV fraction was consistent with that in the soluble fraction for nine proteins. In term preeclampsia, CCL3 had increased abundance in both fractions (q < 0.1). The combined EV and soluble fraction proteomic profiles predicted preterm and term preeclampsia with an AUC of 78% (95% CI, 66%-90%) and 68% (95% CI, 56%-80%), respectively. Three clusters of preeclampsia featuring distinct clinical characteristics and placental pathology were identified based on combined protein data. Our findings reveal distinct alterations of the maternal EV-associated and soluble plasma proteome in preterm and term preeclampsia and identify molecular subgroups of patients with distinct clinical and placental histopathologic features. Show less
📄 PDF DOI: 10.1111/aji.13928
IL27
Yun Xue, You Zhou, Chunyan Li +3 more · 2024 · BMC musculoskeletal disorders · BioMed Central · added 2026-04-24
This study aimed to evaluate the causal relationship between Interleukin-27 (IL-27) and osteoporosis by bidirectional Mendelian randomization (MR) analysis. Firstly, the genome-wide association study Show more
This study aimed to evaluate the causal relationship between Interleukin-27 (IL-27) and osteoporosis by bidirectional Mendelian randomization (MR) analysis. Firstly, the genome-wide association study summary data of osteoporosis (finn-b-M13_OSTEOPOROSIS) and IL-27 levels (ebi-a-GCST90012017) were picked out from the Integrative Epidemiology Unit (IEU) OpenGWAS database. After filtrating instrumental variables (IVs), the bidirectional MR analysis between IL-27 levels and osteoporosis was performed by MR-Egger, Weighted median, Simple mode, Weighted mode, and Inverse variance weighted (IVW). Subsequently, the sensitivity analysis was adopted to evaluate the reliability of the MR results via the Heterogeneity, Horizontal pleiotropy test and Leave-One-Out (LOO) analysis. Finally, the enrichment analysis of genes corresponding to SNPs related to IL-27 levels derived from eQTLGen database was executed to explore in depth the biological function and regulatory mechanism of these genes on osteoporosis occurrence. The bidirectional MR results based on IVW method revealed that IL-27 level as a risk factor was causally related to osteoporosis (P = 0.004, odds ratio (OR) = 1.123, 95% confidence interval (CI) = 1.037-1.217), whereas osteoporosis was not in significant connection with IL-27 levels (P > 0.05). In regard to the sensitivity analysis for forward MR results, there was no heterogeneity and horizontal pleiotropy, and no SNPs relevant to IL-27 levels existed severe bias, suggesting the reliability of forward MR analysis. Furthermore, a total of 74 genes corresponding to 26 SNPs of IL-27 levels were obtained and were mainly involved in immune and inflammatory pathways including MyD88-dependent toll-like receptor signaling pathway, Toll-like receptor signaling pathway, cytosolic DNA-sensing pathway and so forth. This study supported that IL-27 level as a risk factor was causally connected with osteoporosis and might regulate the disease occurrence and progression by means of immune and inflammatory mechanisms, which could provide important reference and evidence for further exploring the role of IL-27 in the development of osteoporosis. Show less
📄 PDF DOI: 10.1186/s12891-024-07765-8
IL27
Nan Jiang, JingLi Zhao, ChuHuan Zhou +1 more · 2024 · Autoimmunity · Taylor & Francis · added 2026-04-24
Chronic periodontitis (CP) and allergic rhinitis (AR) have attracted wide attention as global public health problems with high incidence. Recent studies have shown that circulating interleukin-27 (IL- Show more
Chronic periodontitis (CP) and allergic rhinitis (AR) have attracted wide attention as global public health problems with high incidence. Recent studies have shown that circulating interleukin-27 (IL-27) is associated with the risk of CP and AR. The aim of this study is to analyze the causal effect between them using Mendelian randomization (MR). Bidirectional MR analyses were performed with the use of publicly available genome-wide association study (GWAS) data. Summary data on circulating IL-27, CP, and AR published in genome-wide association studies were collected. Instrumental variables (IV) were extracted using assumptions of correlation, independence and exclusivity as criteria. Inverse variance weighting (IVW) was used as the main method, combined with weighted median method (WM) and MR-Egger and other MR Analysis methods for causal inference of exposure and outcome. Cochran's Q and MR-Egger intercept were used for sensitivity analysis. The IVW study showed a causal effect between increased circulating IL-27 levels and increased risk of CP (OR = 1.14, 95%CI = 1.02-1.26, There is a causal effect between circulating IL-27 level and CP, AR, which will help to find new ideas and methods for the diagnosis and treatment of CP and AR. Show less
no PDF DOI: 10.1080/08916934.2024.2358070
IL27
Jianmin Zhu, Liting Yang, Jing Xia +6 more · 2024 · Transplantation · added 2026-04-24
Stimulation of myeloid-derived suppressor cell (MDSC) formation represents a potential curative therapeutic approach for graft-versus-host disease (GVHD), which significantly impacts the prognosis of Show more
Stimulation of myeloid-derived suppressor cell (MDSC) formation represents a potential curative therapeutic approach for graft-versus-host disease (GVHD), which significantly impacts the prognosis of allogeneic hematopoietic stem cell transplantation. However, the lack of an effective strategy for inducing MDSC production in vivo has hindered their clinical application. In our previous study, MDSC expansion was observed in interleukin (IL)-27-treated mice. In this study, we overexpressed exogenous IL-27 in mice using a recombinant adeno-associated virus vector to investigate its therapeutic and exacerbating effects in murine GVHD models. In our study, we demonstrated that exogenous administration of IL-27 significantly suppressed GVHD development in a mouse model. We found that IL-27 treatment indirectly inhibited the proliferation and activation of donor T cells by rapidly expanding recipient and donor myeloid cells, which act as MDSCs after irradiation or under inflammatory conditions, rather than through regulatory T-cell expansion. Additionally, IL-27 stimulated MDSC expansion by enhancing granulocyte-monocyte progenitor generation. Notably, we verified that IL-27 signaling in donor T cells exerted an antagonistic effect on GVHD prevention and treatment. Further investigation revealed that combination therapy involving IL-27 and T-cell depletion exhibited remarkable preventive effects on GVHD in both mouse and xenogeneic GVHD models. Collectively, these findings suggest that IL-27 promotes MDSC generation to reduce the incidence of GVHD, whereas targeted activation of IL-27 signaling in myeloid progenitors or its combination with T-cell depletion represents a potential strategy for GVHD therapy. Show less
no PDF DOI: 10.1097/TP.0000000000005069
IL27
Katerina Roznik, Temesgen E Andargie, T Scott Johnston +12 more · 2024 · The Journal of infectious diseases · Oxford University Press · added 2026-04-24
Multisystem inflammatory syndrome in children (MIS-C) is a hyperinflammatory condition caused by recent infection with severe acute respiratory syndrome coronavirus 2, but the underlying immunological Show more
Multisystem inflammatory syndrome in children (MIS-C) is a hyperinflammatory condition caused by recent infection with severe acute respiratory syndrome coronavirus 2, but the underlying immunological mechanisms driving this distinct syndrome are unknown. We utilized high-dimensional flow cytometry, cell-free (cf) DNA, and cytokine and chemokine profiling to identify mechanisms of critical illness distinguishing MIS-C from severe acute coronavirus disease 2019 (SAC). Compared to SAC, MIS-C patients demonstrated profound innate immune cell death and features of emergency myelopoiesis (EM), an understudied phenomenon observed in severe inflammation. EM signatures were characterized by fewer mature myeloid cells in the periphery and decreased expression of HLA-DR and CD86 on antigen-presenting cells. Interleukin 27 (IL-27), a cytokine known to drive hematopoietic stem cells toward EM, was increased in MIS-C, and correlated with immature cell signatures in MIS-C. Upon recovery, EM signatures decreased and IL-27 plasma levels returned to normal levels. Despite profound lymphopenia, we report a lack of cfDNA released by adaptive immune cells and increased CCR7 expression on T cells indicative of egress out of peripheral blood. Immune cell signatures of EM combined with elevated innate immune cell-derived cfDNA levels distinguish MIS-C from SAC in children and provide mechanistic insight into dysregulated immunity contributing toward MIS-C, offering potential diagnostic and therapeutic targets. Show less
📄 PDF DOI: 10.1093/infdis/jiae032
IL27
Peihua Li, Shiming Pu, Jiequn Yi +6 more · 2024 · International immunopharmacology · Elsevier · added 2026-04-24
Colorectal cancer (CRC) is a leading cause of cancer-related deaths worldwide, characterized by molecular and clinical heterogeneity. Interleukin (IL)-27, a heterodimeric cytokine composed of p28 and Show more
Colorectal cancer (CRC) is a leading cause of cancer-related deaths worldwide, characterized by molecular and clinical heterogeneity. Interleukin (IL)-27, a heterodimeric cytokine composed of p28 and EBI3 subunits, has been reported to exert potent antitumor activity in several cancer models. However, the precise role of IL-27 in the pathogenesis of CRC remains unclear. Here, we show that during the azoxymethane (AOM)/dextran sodium sulfate (DSS)-induced CRC development, IL-27p28 levels are dramatically increased in peripheral blood and tumor tissues, and the cytokine is mainly produced by tumor-infiltrating myeloid cells. IL-27p28 deficient mice display tumor resistances in both inflammation-associated CRC model and syngeneic MC38 colon cancer model. Administration with IL-27p28 neutralizing antibody also reduces the tumor formation in AOM/DSS-treated mice. Mechanically, CD8 Show less
no PDF DOI: 10.1016/j.intimp.2023.111464
IL27
Xingmei Guo, Zhini Xiao, Haimin Xu +10 more · 2024 · International journal of surgical pathology · SAGE Publications · added 2026-04-24
no PDF DOI: 10.1177/10668969231217632
JMJD1C
Yun-Lu Lin, Tao Yao, Ying-Wei Wang +6 more · 2024 · Journal of human genetics · Nature · added 2026-04-24
Gastroesophageal reflux disease (GERD) is a prevalent chronic ailment, and present therapeutic approaches are not always effective. This study aimed to find new drug targets for GERD and Barrett's eso Show more
Gastroesophageal reflux disease (GERD) is a prevalent chronic ailment, and present therapeutic approaches are not always effective. This study aimed to find new drug targets for GERD and Barrett's esophagus (BE). We obtained genetic instruments for GERD, BE, and 2004 plasma proteins from recently published genome-wide association studies (GWAS), and Mendelian randomization (MR) was employed to explore potential drug targets. We further winnowed down MR-prioritized proteins through replication, reverse causality testing, colocalization analysis, phenotype scanning, and Phenome-wide MR. Furthermore, we constructed a protein-protein interaction network, unveiling potential associations among candidate proteins. Simultaneously, we acquired mRNA expression quantitative trait loci (eQTL) data from another GWAS encompassing four different tissues to identify additional drug targets. Meanwhile, we searched drug databases to evaluate these targets. Under Bonferroni correction (P < 4.8 × 10 Show less
📄 PDF DOI: 10.1038/s10038-024-01234-9
LINGO1
Yu-Han Xie, Lin Jiang, Yi Zhang +12 more · 2024 · Neuroscience letters · Elsevier · added 2026-04-24
In Alzheimer's disease (AD), microglia are involved in synaptic pruning and mediate synapse loss. LINGO-1 is a negative regulator of nerve growth, and whether antagonizing LINGO-1 can attenuate synapt Show more
In Alzheimer's disease (AD), microglia are involved in synaptic pruning and mediate synapse loss. LINGO-1 is a negative regulator of nerve growth, and whether antagonizing LINGO-1 can attenuate synaptic pruning by microglia and rescue dendritic spines in the hippocampus in AD is still unclear. On this basis, the anti-LINGO-1 antibody, which binds to LINGO-1 protein and antagonizes the effects of LINGO-1, was administered to 10-month-old APP/PS1 transgenic mice for 2 months. The Morris water maze test, immunohistochemical and stereological methods, immunofluorescence and 3D reconstruction were used. Compared to wild-type mice, APP/PS1 transgenic mice had worse performance on behavioral tests, fewer dendritic spines but more microglia in the hippocampus. Meanwhile, the microglia in APP/PS1 transgenic mice had more branches of medium length (4-6 µm) and a cell body area with greater variability. Moreover, APP/PS1 transgenic mice had more postsynaptic termini colocalized with microglia in the hippocampus than wild-type mice. The anti-LINGO-1 antibody significantly reversed these changes in AD, indicating that the anti-LINGO-1 antibody can improve hippocampus-dependent learning and memory abilities and effectively rescue dendritic spines in the hippocampus of AD mice and that microglia might participate in this progression in AD. These results provide a scientific basis for further studying the mechanism of the anti-LINGO-1 antibody in AD and help to elucidate the role of LINGO-1 in the treatment of AD. Show less
no PDF DOI: 10.1016/j.neulet.2023.137612
LINGO1
Jie-Pin Li, Yuan-Jie Liu, Yang Li +7 more · 2024 · Journal of translational medicine · BioMed Central · added 2026-04-24
Cellular communication (CC) influences tumor development by mediating intercellular junctions between cells. However, the role and underlying mechanisms of CC in malignant transformation remain unknow Show more
Cellular communication (CC) influences tumor development by mediating intercellular junctions between cells. However, the role and underlying mechanisms of CC in malignant transformation remain unknown. Here, we investigated the spatiotemporal heterogeneity of CC molecular expression during malignant transformation. It was found that although both tight junctions (TJs) and gap junctions (GJs) were involved in maintaining the tumor microenvironment (TME), they exhibited opposite characteristics. Mechanistically, for epithelial cells (parenchymal component), the expression of TJ molecules consistently decreased during normal-cancer transformation and is a potential oncogenic factor. For fibroblasts (mesenchymal component), the expression of GJs consistently increased during normal-cancer transformation and is a potential oncogenic factor. In addition, the molecular profiles of TJs and GJs were used to stratify colorectal cancer (CRC) patients, where subtypes characterized by high GJ levels and low TJ levels exhibited enhanced mesenchymal signals. Importantly, we propose that leiomodin 1 (LMOD1) is biphasic, with features of both TJs and GJs. LMOD1 not only promotes the activation of cancer-associated fibroblasts (CAFs) but also inhibits the Epithelial-mesenchymal transition (EMT) program in cancer cells. In conclusion, these findings demonstrate the molecular heterogeneity of CC and provide new insights into further understanding of TME heterogeneity. Show less
📄 PDF DOI: 10.1186/s12967-024-05369-3
LMOD1
Yanhua Zhou, Dayu Yan, Xiulan Zhang +3 more · 2024 · Zhong nan da xue xue bao. Yi xue ban = Journal of Central South University. Medical sciences · added 2026-04-24
Pelvic organ prolapse (POP) is a common condition in postmenopausal women, with an increasing prevalence due to aging. Some women experience POP recurrence after surgical treatment, significantly affe Show more
Pelvic organ prolapse (POP) is a common condition in postmenopausal women, with an increasing prevalence due to aging. Some women experience POP recurrence after surgical treatment, significantly affecting their physical and mental health. The uterosacral ligament is a critical pelvic support structure. This study aims to investigate the molecular pathological changes in the uterosacral ligament of postmenopausal women with recurrent POP using transcriptomic analysis. Transcriptomic data of uterosacral ligament tissues were obtained from the public dataset GSE28660, which includes samples from 4 postmenopausal women with recurrent POP, 4 with primary POP, and 4 without POP. Differentially expressed genes (DEGs) were identified between recurrent POP and both primary and non-POP groups. Further analysis included intersection analysis of DEGs, gene ontology enrichment, protein-protein interaction (PPI) network construction, gene set enrichment analysis (GSEA), single-sample GSEA, and xCell immune cell infiltration analysis to explore molecular pathological changes in recurrent POP. Additionally, histological and molecular differences in the uterosacral ligament were compared between simulated vaginal delivery (SVD) rat models with and without ovariectomy. Compared with primary POP and non-POP groups, recurrent POP exhibited activation of adipogenesis and inflammation-related pathways, while pathways related to muscle proliferation and contraction were downregulated in the uterosacral ligament. Nine key DEGs ( Adipogenesis and inflammation in the uterosacral ligament may contribute to its reduced supportive function, potentially leading to recurrence POP in postmenopausal women. Show less
📄 PDF DOI: 10.11817/j.issn.1672-7347.2024.230308
LPL
Yujie Li, Ke Xu, Ao Zhou +5 more · 2024 · Genes · MDPI · added 2026-04-24
📄 PDF DOI: 10.3390/genes15121562
LPL
Hongmeng Zhao, Xuejie Zhou, Guixin Wang +9 more · 2024 · Journal of Cancer · added 2026-04-24
📄 PDF DOI: 10.7150/jca.101042
LPL
Tam Nguyen, Christina Chang, David Cipolla +5 more · 2024 · Expert opinion on drug delivery · Taylor & Francis · added 2026-04-24
To determine key enzymes enabling treprostinil palmitil (TP) conversion to treprostinil and the main converting sites in the respiratory system. We performed in vitro activity assays to identify lung Show more
To determine key enzymes enabling treprostinil palmitil (TP) conversion to treprostinil and the main converting sites in the respiratory system. We performed in vitro activity assays to identify lung enzymes hydrolyzing TP, and cell-based assays and immunostainings to establish the likely locations within the lung. Lipoprotein lipase (LPL) had greater activity than the other tested lung enzymes. Excess LPL activity was present both in vitro and at the target TP dose in vivo. LPL is likely the key enzyme enabling TP conversion. The rate-limiting step is likely the accessibility of TP and not the enzyme activity. Show less
no PDF DOI: 10.1080/17425247.2024.2395444
LPL
Sheng Li, Yuyan Wang, Siyu Guo +4 more · 2024 · Journal of animal science · Oxford University Press · added 2026-04-24
Incubation temperature is a crucial environmental factor affecting embryonic development and chick quality. Metabolism during the embryonic stage, particularly liver lipid metabolism, is essential for Show more
Incubation temperature is a crucial environmental factor affecting embryonic development and chick quality. Metabolism during the embryonic stage, particularly liver lipid metabolism, is essential for the growth and development of poultry. This study aimed to investigate the effects of embryo thermal manipulation with high (TMH, 39.5 °C, 65% RH, 8 h/d) and low (TML, 20 °C, 65% RH, 1 h/d) temperatures during 8th to 15th embryonic age on hatching performance and liver lipid metabolism in layer chicks. Additionally, the duration of TM effects was evaluated through a short-term feeding trial. The results indicated that TMH accelerated the hatching process without significantly affecting hatchability and growth performance. In contrast, TML delayed hatching time and significantly reduced hatchability and chick quality. After hatching, TML also increased residual yolk weight and reduced the relative liver weight in relation to body weight and yolk-free body mass. Moreover, lipid droplets in the liver were stained with Oil Red O, and the lipid content in the liver and serum was further detected. TMH had no significant impact on triglyceride (TG) and total-cholesterol (TCHO) content in the liver and serum but upregulated the expression of lipogenesis-related genes ACC, Fas, and Fatp1 compared to the TML group. Conversely, TML significantly reduced liver TG content, enhanced lipoprotein lipase (LPL) activity, and promoted the expression of lipid oxidation-related genes CPT-1, PGC-1α, and PPARα. At 7 d of age, liver LPL activity was significantly increased in the TMH group. However, there were no significant changes in the content of TG and TCHO in the liver and the expression of lipid metabolism-related genes in the TML group. Overall, these results indicate that embryonic TM alters hatching performance and liver lipid metabolism in layer chicks. TML reduces TG content by increasing liver lipid oxidation capacity. However, this effect is not long-lasting, as the influence of TM diminishes as the chicks develop. Show less
📄 PDF DOI: 10.1093/jas/skae242
LPL
Hongji Zhou, Rui Zhang, Min Li +5 more · 2024 · Journal of immunology research · added 2026-04-24
It has been reported that carbonic anhydrase I (CA1) is a target for the diagnosis and therapy of atherosclerosis (AS) since CA1 can promote AS aortic calcification. We also found that methazolamide ( Show more
It has been reported that carbonic anhydrase I (CA1) is a target for the diagnosis and therapy of atherosclerosis (AS) since CA1 can promote AS aortic calcification. We also found that methazolamide (MTZ), a drug for glaucoma treatment and an inhibitor of carbonic anhydrases, can treat AS by inhibiting calcification in aortic tissues. This study focused on the therapeutic mechanism of MTZ and the pathogenic mechanism of AS. In this study, a routine AS animal model was established in ApoE-/- mice, which were treated with MTZ. The aortic tissues were analyzed using single-cell sequencing. MTZ significantly increased the proportions of B-1/MZB B cells with high expressions of Nr4A1 and Ccr7, CD8+CD122+ Treg-like cells with high Nr4A1 expression, and smooth muscle cells with high Tpm2 expression. These cells or their marker genes were reported to exert immunosuppressive, anti-proinflammatory, and atheroprotective effects. MTZ also decreased the proportions of endothelial cells with high expressions of Retn, Apoc1, Lcn2, Mt1, Serpina3, Lpl, and Lgals3; nonclassical CD14+CD16++ monocytes with high expressions of Mt1, Tyrobp, Lgals3, and Cxcl2; and Spp1+ macrophages with high expressions of Mmp-12, Trem2, Mt1, Lgals3, Cxcl2, and Lpl. These cells or their marker genes have been reported to promote inflammation, calcification, tissue remodeling, and atherogenesis. A significant decrease in the proportion of CD8+CD183 (CXCR3)+ T cells, the counterpart of murine CD8+CD122+ T cells, was detected in the peripheral blood of newly diagnosed AS patients rather than in that of patients receiving anti-AS treatments. These results suggest that MTZ can treat AS by increasing immunosuppressive cells and decreasing expressions of genes related to inflammation, calcification, and tissue remodeling. Show less
📄 PDF DOI: 10.1155/2024/5009637
LPL
Huan Zhou, Hui Zheng, Yucai Peng +15 more · 2024 · Frontiers in immunology · Frontiers · added 2026-04-24
We aimed to evaluate the efficacy, safety, and immunogenicity of a SARS-CoV-2 mRNA vaccine (Omicron BA.5) LVRNA012 given as the booster in immunized but SARS-CoV-2 infection-free adults in China. This Show more
We aimed to evaluate the efficacy, safety, and immunogenicity of a SARS-CoV-2 mRNA vaccine (Omicron BA.5) LVRNA012 given as the booster in immunized but SARS-CoV-2 infection-free adults in China. This is a single-center, randomized, double-blind, placebo-controlled phase 3 clinical trial enrolling healthy adult participants (≥18 years) who had completed two or three doses of inactivated COVID-19 vaccines at least 6 months before, in Bengbu, Anhui province, China. Eligible participants were randomly assigned (1:1) to receive a booster intramuscular vaccination with an LVRNA012 vaccine (100ug) or placebo. The primary endpoint was the protective efficacy of a booster dose of the LVRNA012 vaccine or placebo against symptomatic COVID-19 of any severity 14 days after vaccination. Laboratory-confirmed COVID-19 infections were identified from 14 days to 180 days after intervention, with active surveillance for symptomatic illness 8 times per month between 7 to 90 days and at least once per month between 90 to 180 days after intervention. 2615 participants were recruited and randomly assigned in a 1:1 ratio to either the vaccine group (1308) or the placebo group (1307). A total of 141 individuals (46 in the LVRNA012 group and 95 in the placebo group) developed symptomatic COVID-19 infection 14 days after the booster immunization, showing a vaccine efficacy of 51.9% (95% CI, 31.3% to 66.4%). Most infections were detected 90 days after intervention during a period when XBB was prevalent in the community. Adverse reactions were reported by 64% of participants after the LVRNA012 vaccination, but most of them were mild or moderate. The booster vaccination with the LVRNA012 mRNA vaccine could significantly enhance neutralizing antibody titers against the Omicron variant XBB.1.5 (GMT 132.3 [99.8, 175.4]) than did those in the placebo group (GMT 12.5 [8.4, 18.7]) at day 14 for the previously immunized individuals. The LVRNA012 mRNA vaccine is immunogenic, and shows robust efficacy in preventing COVID-19 during the omicron-predominate period. ClinicalTrials.gov, identifier NCT05745545. Show less
📄 PDF DOI: 10.3389/fimmu.2024.1407826
LPL
Zengwen Huang, Jing Wang, Dongming Qi +7 more · 2024 · PloS one · PLOS · added 2026-04-24
The Butuo Black Sheep (BBS) is well-known for its ability to thrive at high altitudes, resist diseases, and produce premium-quality meat. Nonetheless, there is insufficient data regarding its genetic Show more
The Butuo Black Sheep (BBS) is well-known for its ability to thrive at high altitudes, resist diseases, and produce premium-quality meat. Nonetheless, there is insufficient data regarding its genetic diversity and population-specific Single nucleotide polymorphisms (SNPs). This paper centers on the genetic diversity of (BBS). The investigation conducted a whole-genome resequencing of 33 BBS individuals to recognize distinct SNPs exclusive to BBS. The inquiry utilized bioinformatic analysis to identify and explain SNPs and pinpoint crucial mutation sites. The findings reveal that reproductive-related genes (GHR, FSHR, PGR, BMPR1B, FST, ESR1), lipid-related genes (PPARGC1A, STAT6, DGAT1, ACACA, LPL), and protein-related genes (CSN2, LALBA, CSN1S1, CSN1S2) were identified as hub genes. Functional enrichment analysis showed that genes associated with reproduction, immunity, inflammation, hypoxia, PI3K-Akt, and AMPK signaling pathways were present. This research suggests that the unique ability of BBS to adapt to low oxygen levels in the plateau environment may be owing to mutations in a variety of genes. This study provides valuable insights into the genetic makeup of BBS and its potential implications for breeding and conservation efforts. The genes and SPNs identified in this study could serve as molecular markers for BBS. Show less
📄 PDF DOI: 10.1371/journal.pone.0303419
LPL
Yingyi Li, Hehui Cai, Yancheng Lin +7 more · 2024 · Archives of endocrinology and metabolism · added 2026-04-24
The study aims to explore the relationship between lipoprotein lipase In total, 80 participants were involved in this study (54 patients with HLAP and 26 controls). All coding regions and intron-exon Show more
The study aims to explore the relationship between lipoprotein lipase In total, 80 participants were involved in this study (54 patients with HLAP and 26 controls). All coding regions and intron-exon boundaries of the The rate of rare Detecting rare variants in Show less
📄 PDF DOI: 10.20945/2359-4292-2023-0195
LPL